Suzhou Sanegene Bio Inc.’s clinical trial application for SGB-3908 injection, an siRNA drug for the treatment of hypertension, has been accepted in China by the National Medical Products Administration (NMPA)’s Center for Drug Evaluation (CDE).
α-Fetoprotein (AFP) is a tumor-associated antigen and an ideal target for T-cell receptor T-cell (TCR-T) therapy. While the safety of AFP-targeting TCR-T products has been previously demonstrated in early clinical trials, the efficacy of these cell therapies is still modest, warranting further research.
Previous findings had shown that injecting pepatin-1 prevented the death of retinal ganglion cells (RGCs) in rats with ocular hypertension. Additionally, transcriptomic analysis in RGCs revealed cAMP response element-binding protein (CREB) signaling to be activated by peptain-1 conjugated with a cell-penetrating peptide, named P1-CPP.
Saniona AB has initiated preclinical development of SAN-2355, a potential best-in-class and new-generation Kv7.2/Kv7.3 activator for the treatment of focal onset seizures.
Seragon Biosciences Inc. has completed a preclinical study with its novel antiaging candidate, SRN-901. This pivotal study in mice evaluated the impact of SRN-901 on aging as well as various health markers.
Researchers from Huazhong University of Science and Technology and collaborators published results from a study that aimed to assess the potential role of caveolin 3 (CAV3) in mitochondrial function during diabetic cardiomyopathy (DCM).
Sepsis occurs when there is a dysregulated host response to infection, resulting in organ dysfunction. According to the Global Burden of Disease study, about 50 million people annually worldwide develop severe sepsis or septic shock, and 11 million of them die. Growing evidence suggests that changes to the vascular endothelium, which becomes more permeable to fluid, protein and inflammatory cells, are behind the pathogenesis of sepsis and septic shock.
Kymera Therapeutics Inc. has described salts of IL-1 receptor-associated kinase 4 (IRAK-4) degradation inducers and their crystalline forms reported to be useful for the treatment of autoimmune diseases and inflammatory disorders.